GT Biopharma Files 8-K on Security Holder Rights
Ticker: GTBP · Form: 8-K · Filed: Sep 23, 2025 · CIK: 109657
| Field | Detail |
|---|---|
| Company | Gt Biopharma, INC. (GTBP) |
| Form Type | 8-K |
| Filed Date | Sep 23, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing-update
TL;DR
GT Biopharma filed an 8-K on 9/23 for events on 9/17, detailing changes to security holder rights. Check it out.
AI Summary
GT Biopharma, Inc. filed an 8-K on September 23, 2025, reporting events as of September 17, 2025. The filing indicates material modifications to the rights of security holders and includes financial statements and exhibits. The company, formerly known as OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS INC, and DIAGNOSTIC DATA INC /DE/, is incorporated in Delaware and based in San Francisco, CA.
Why It Matters
This 8-K filing signals potential changes affecting GT Biopharma's shareholders, requiring investors to review the details of any modifications to their rights.
Risk Assessment
Risk Level: medium — Filings related to modifications of security holder rights can indicate significant corporate actions or changes that may impact stock value and investor positions.
Key Players & Entities
- GT Biopharma, Inc. (company) — Registrant
- OXIS INTERNATIONAL INC (company) — Former Company Name
- DDI PHARMACEUTICALS INC (company) — Former Company Name
- DIAGNOSTIC DATA INC /DE/ (company) — Former Company Name
- September 17, 2025 (date) — Earliest event date reported
- September 23, 2025 (date) — Report date
FAQ
What specific modifications were made to the rights of GT Biopharma's security holders?
The filing indicates 'Material Modifications to Rights of Security Holders' as an item of disclosure, but the specific details of these modifications are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 17, 2025.
What is the primary business of GT Biopharma, Inc. according to its SIC code?
According to its Standard Industrial Classification (SIC) code 2834, GT Biopharma, Inc. is in the business of Pharmaceutical Preparations.
What are the former names of GT Biopharma, Inc. mentioned in the filing?
The filing lists former names including OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS INC, and DIAGNOSTIC DATA INC /DE/.
Where is GT Biopharma, Inc. incorporated and what is its principal business address?
GT Biopharma, Inc. is incorporated in Delaware and its principal business address is 505 Montgomery Street, 10th Floor, San Francisco, CA 94111.
Filing Stats: 564 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2025-09-23 17:30:50
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value GTBP The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex10-1.htm (EX-10.1) — 15KB
- 0001493152-25-014684.txt ( ) — 217KB
- gtbp-20250917.xsd (EX-101.SCH) — 3KB
- gtbp-20250917_lab.xml (EX-101.LAB) — 33KB
- gtbp-20250917_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GT BIOPHARMA, INC. Date: September 23, 2025 By: /s/ Alan Urban Alan Urban Chief Financial Officer